通过调节炎酶激活,TIM-3抑制抗瘤免疫力
Karen O Dixon1,2,3, Marcin Tabaka3, Markus A Schramm1,2,4
1Evergrande Center for Immunologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Nature
|June 10, 2021
概括
阻断T细胞免疫球蛋白和含有粘素的分子3 (TIM-3) 在树突细胞上,而不是T细胞,增强了抗瘤免疫力. 在树突细胞上丧失TIM-3会激活NLRP3炎症体,这对这种免疫反应至关重要.
科学领域:
- 免疫学
- 癌症生物学
- 细胞免疫学
背景情况:
- T细胞免疫球蛋白和含粘素分子3 (TIM-3) 是癌症治疗的免疫检查点分子.
- 在CD8+T细胞上TIM-3表达意味着功能障碍,但其在其他免疫细胞上的存在使治疗策略复杂化.
研究的目的:
- 研究TIM-3在瘤微环境中的不同免疫细胞中的特定作用.
- 阐明TIM-3阻塞促进抗瘤免疫力的机制.
主要方法:
- 条件淘汰模型的TIM-3.
- 一个单细胞RNA测序.
- 免疫细胞群和细胞因子生产的分析.
主要成果:
- 特别针对树突细胞 (DCs) 而非T细胞的TIM-3损失显著增强了抗瘤免疫力.
- 在DC中删除TIM-3阻止了调控程序,促进了CD8+效应细胞和干细胞T细胞.
- 在DC中TIM-3的缺失导致了反应性氧物种的积累,NLRP3炎症酶的激活,以及随后的IL-1β和IL-18的产生.
结论:
- 在调节树突细胞功能方面,TIM-3起着至关重要的作用.
- 通过DCs的炎症酶激活,提升了TIM-3阻塞的抗瘤免疫力.
- 针对树突细胞的TIM-3是癌症免疫疗法的有希望的治疗策略.
更多相关视频
相关概念视频
The Tumor Microenvironment
7.1K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.1K
Abnormal Proliferation
4.8K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Tumor Immunotherapy
791
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
791
T Cell Types and Functions
1.6K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.6K
mTOR Signaling and Cancer Progression
4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.0K
TGF - β Signaling Pathway
8.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.2K


